Table I.
Demographic and clinical characteristics of the study groups
| Parameter | PSO (N=7) | Healthy (N=7) | P |
|---|---|---|---|
|
| |||
| Demographics and medical history | |||
|
| |||
| Age (years) | 42.29 ± 6.38 | 41.71 ± 4.98 | 0.47 |
| Male sex, n (%) | 3 (43) | 5 (71) | 0.28 |
| Ethnicity, whites (%) | 7 (100) | 7 (100) | 1.00 |
| Body mass index (kg/m2) | 27.94 ± 1.43 | 27.16 ± 2.26 | 0.39 |
| Hypertension, n (%) | 1 (14) | 2 (28) | 0.52 |
| Hyperlipidemia, n (%) | 3 (43) | 3 (43) | 1.00 |
| Type 2 diabetes mellitus, n (%) | 1 (14) | 0 (0) | 0.30 |
| Current tobacco use, n (%) | 0 (0) | 0 (0) | 1.00 |
| Current alcohol use, n (%) | 0 (0) | 0 (0) | 1.00 |
|
| |||
| Clinical and laboratory values | |||
|
| |||
| Systolic blood pressure (mmHg) | 120.0 ± 4.70 | 114.3 ± 5.19 | 0.22 |
| Diastolic Blood Pressure (mmHg) | 70.57 ± 2.13 | 71.86 ± 5.04 | 0.41 |
| Total cholesterol (mg/dl) | 189.3 ± 14.95 | 186.1 ± 13.32 | 0.44 |
| Triglycerides (mg/dl) | 112.4 ± 17.07 | 170.0 ± 68.11 | 0.21 |
| HDL cholesterol (mg/dl) | 57.14 ± 3.85 | 56.00 ± 5.64 | 0.44 |
| LDL cholesterol (mg/dl) | 109.7 ± 11.06 | 97.00 ± 9.30 | 0.20 |
| ApoA1 (mg/L) | 164.0 ± 7.05 | 153.6 ± 6.87 | 0.16 |
| ApoB (mg/L) | 94.43 ± 8.30 | 81.71 ± 6.88 | 0.26 |
| ApoB / ApoA 1 | 0.76 ± 0.18 | 0.54 ± 0.05 | 0.14 |
| FRS (IQR) | 1 (1–6) | 1 (1–7) | 0.94 |
| hsCRP (mg/L) (IQR) | 3.77 (3.12–10.4) | 1 (0.7–1.5) | 0.002 |
| Glucose (mg/dl) | 105.30 ± 12.19 | 92.50 ± 3.32 | 0.18 |
| Insulin (mg/dl) | 10.63 ± 2.44 | 20.27 ± 12.15 | 0.23 |
| WBC (cells/L) | 6.46 ± 0.82 | 11.93 ± 6.88 | 0.22 |
|
| |||
| Psoriasis Severity and Treatment | |||
|
| |||
| Disease duration (years) | 17.29±3.93 | ||
| PASI score (IQR) | 7.7 (6.6–12.3) | ||
| Psoriatic arthritis, n (%) | 4 (57.14) | ||
| Topical therapy, n (%) | 5 (71.43) | ||
| Biologic therapy, n (%) | 2 (28.57) | ||
| Systemic therapy, n (%) | 0 (0) | ||
FRS, Framingham Risk Score; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range; LDL, low-density lipoprotein; PASI, psoriasis area and severity index; PSO, psoriasis; WBC, white blood cell. Data are mean±SE or median (Interquartile Range) for parametric and non-parametric variables respectively and as N (%) for categorical variables. P values were derived from a single unpaired 2-tailed t test for parametric variables and the Mann-Whitney test for non-parametric variables. The Pearson’s Chi-square test was used for categorical variables. P<0.05 was considered statistically significant.